{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:07:13Z","timestamp":1781280433570,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023554","name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Case Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eucr.2026.103342","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:48:08Z","timestamp":1768031288000},"page":"103342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recurrent bladder paraganglioma with peritoneal dissemination: An unusual pattern of metastatic progression. Case report and literature review"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1873-7241","authenticated-orcid":false,"given":"Paolo Guedes","family":"Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Jim\u00e9nez","family":"Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n Espino","family":"Espino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinaldo","family":"Marrero Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Exp\u00f3sito Remedios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Camacho","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eucr.2026.103342_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and Paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eucr.2026.103342_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"7","key":"10.1016\/j.eucr.2026.103342_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.02.006","article-title":"Genitourinary paraganglioma: demographic, pathologic, and clinical characteristics in the surveillance, epidemiology, and end results database (2000-2012)","volume":"35","author":"Purnell","year":"2017","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.eucr.2026.103342_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/cen.15058","article-title":"Diagnosis and management of urinary bladder paragangliomas: a Sino-American-European retrospective observational study","volume":"101","author":"Pang","year":"2024","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.eucr.2026.103342_bib5","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1210\/clinem\/dgac427","article-title":"Presentation, management, and outcomes of urinary bladder paraganglioma: results from a multicenter study","volume":"107","author":"Yu","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eucr.2026.103342_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00345-021-03851-x","article-title":"Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review","volume":"40","author":"Li","year":"2022","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.eucr.2026.103342_bib7","doi-asserted-by":"crossref","first-page":"167.e13","DOI":"10.1016\/j.urolonc.2014.11.017","article-title":"Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes","volume":"33","author":"Martucci","year":"2015","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.eucr.2026.103342_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.eucr.2026.103342_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.eucr.2026.103342_bib10","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/endrev\/bnad011","article-title":"Biochemical assessment of pheochromocytoma and Paraganglioma","volume":"44","author":"Eisenhofer","year":"2023","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.eucr.2026.103342_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/endrev\/bnae001","article-title":"Imaging of pheochromocytomas and paragangliomas","volume":"45","author":"Timmers","year":"2024","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.eucr.2026.103342_bib12","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s00261-022-03443-2","article-title":"Bladder paragangliomas: a pictorial review","volume":"47","author":"Withey","year":"2022","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"10.1016\/j.eucr.2026.103342_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2025.101977","article-title":"Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"39","author":"Fischer","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"25","key":"10.1016\/j.eucr.2026.103342_bib14","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.eucr.2026.103342_bib15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or Paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.eucr.2026.103342_bib16","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3390\/jcm12041494","article-title":"Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: a systematic review and meta-analysis","volume":"12","author":"Marretta","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.eucr.2026.103342_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1507\/endocrj.EJ20-0762","article-title":"Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy","volume":"68","author":"Fujiwara","year":"2021","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.eucr.2026.103342_bib18","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.eucr.2026.103342_bib19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1210\/clinem\/dgac657","article-title":"Efficacy and safety of tyrosine kinase inhibitors in patients with metastatic Pheochromocytomas\/Paragangliomas","volume":"108","author":"Zhou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eucr.2026.103342_bib20","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2504964","article-title":"Belzutifan for advanced pheochromocytoma or Paraganglioma","author":"Jimenez","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Urology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026000057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026000057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:42:51Z","timestamp":1781278971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214442026000057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"alternative-id":["S2214442026000057"],"URL":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103342","relation":{},"ISSN":["2214-4420"],"issn-type":[{"value":"2214-4420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent bladder paraganglioma with peritoneal dissemination: An unusual pattern of metastatic progression. Case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Urology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103342"}}